Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;21(10):2462-2472.
doi: 10.1016/j.cgh.2023.04.030. Epub 2023 May 8.

Potential Value of Biomarker-Based Approaches for Evaluation and Management of Costly Functional Gastrointestinal Diseases

Michael Camilleri  1 , Joelle BouSaba  2
Affiliations
Review

Potential Value of Biomarker-Based Approaches for Evaluation and Management of Costly Functional Gastrointestinal Diseases

Michael Camilleri et al. Clin Gastroenterol Hepatol. 2023 Sep.
No abstract available

Keywords: Biomarkers; Cost-Effectiveness; Irritable Bowel Syndrome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Examples of actionable biomarkers and individualized therapies for rectal evacuation disorders, abnormal colonic transit, increased fecal bile acids, abnormal breath tests, inflammatory responses to dietary antigen injection into rectosigmoid colon mucosa, hypervigilance identified with validated questionnaires and altered fecal microbiome associated with increased H2S or CH4 excretion in breath (adapted from ref.).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics. 2000;17(4):331–8. Epub 2000/08/18. - PubMed
    1. Drossman DA, Chang L, Deutsch JK, et al. A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. Gastroenterology. 2021;161(5):1670–88.e7. Epub 2021/08/01. - PubMed
    1. Almario CV, Noah BD, Jusufagic A, et al. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers. Clin Gastroenterol Hepatol. 2018;16(9):1434–41.e21. Epub 2018/03/30. - PMC - PubMed
    1. Goodoory VC, Ng CE, Black CJ, et al. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022;56(1):110–20. Epub 2022/05/03. - PMC - PubMed
    1. Black CJ, Ng CE, Goodoory VC, et al. Novel Symptom Subgroups in Individuals With Irritable Bowel Syndrome Predict Disease Impact and Burden. Clin Gastroenterol Hepatol. 2023. Epub 2023/03/02. - PubMed

Publication types